期刊文献+

α1受体阻滞剂治疗良性前列腺增生合并高血压研究进展 被引量:18

Progress in the Studies of α1-Adrenoceptor Blocker for Concurrent Benign Prostatic Hyperplasia and Hypertension
在线阅读 下载PDF
导出
摘要 流行病学调查提示原发性高血压是BPH发生和进展的独立危险因素之一,60岁以上的老年男性中25%同时患有BPH和高血压,严重影响着老年人的生活质量。关于BPH合并高血压的合理治疗方案,目前国内外的文献资料甚少,而且存在很大的争议。现对α1受体阻滞剂治疗BPH合并高血压的研究进展作一综述,分析其疗效,探讨其目前所面临的主要问题及可能的原因,并对其发展前景予以展望。 The epidemiological survey shows that primary hypertension is one of the independent risk factors in the development and the progress of BPH, 25 percent of old male patients aged 60 or more suffer from the two diseases at the same time, which grievously affects their quality of life. There is little literature about the appropriate therapeutic regimen of BPH associated hypertension. The article reviews the progress in the studies of α1-adrenoceptor blocker for BPH associated hypertension, and explores the main problems facing us and ventures the prospects for the development in this field.
出处 《中华男科学杂志》 CAS CSCD 2007年第9期830-834,共5页 National Journal of Andrology
关键词 良性前列腺增生 高血压 Α1受体阻滞剂 benign prostatic hyperplasia hypertension α1-adrenoceptor blocker
  • 相关文献

参考文献30

  • 1Oesterling JE.Benign prostatic hyperplasia,medical and minimally invasive treatment options[J].N Eng J Med,1995,332(2):99-109.
  • 2He J,Whelton PK.Epidemiology and prevention of hypertension[J].Med Clin North Am,1997,81(5):1077-1097.
  • 3Hammarsten J,Hogstedt B.Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia[J].Euro Urol,2001,39(2):151-158.
  • 4Matityahou A,Rosenzweig N,Golomb E,et al.Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats:A model of spontaneous hypertension and prostate hyperplasia[J].J Androl,2003,24(2):263-269.
  • 5Kobayashi S,Tang R,Shapiro E,et al.Characterization and localization of prostatic alpha1 adrenoceptors using radioligand binding on slide-mounted tissue section[J].J Urol,1993,150(6):2002-2006.
  • 6Nasu K,Moriyama N,Kawabe K,et al.Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human prostate:comparison of benign hypertrophied tissue and non-hypertrophied tissue[J].Br J Pharmacol,1996,119(6):797-803.
  • 7Muramatsu I,Taniguchi T,Okada K.Tamsulosin:alpha1 adrenoceptor subtype 2 selectivity and comparison with terazosin[J].Jpn J Pharmacol,1998,78(3):331-335.
  • 8Taniguchi N,Ukai Y,Tanaka T,et al.Identification of alpha1-adrenoceptor subtypes in the human prostatic urethra[J].Naunyn Schmiedebergs Arch Pharmacol,1997,355 (3):412-416.
  • 9Yashiyama M,De Groat WC.Role of spinal alpha-adrenoceptor subtypes in the bladder reflex in anesthetized rats[J].Am J Physiol Regul Integr Comp Physiol,2001,280 (5):R1414-1419.
  • 10Marinese D,Patel R,Walden PD,et al.Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice[J].Prostate,2003,54(3):230-237.

二级参考文献29

  • 1王健,齐晓涟,张乃文,王振纲.近期良性前列腺增生症药物治疗及不良反应进展[J].中国全科医学,2004,7(11):823-825. 被引量:20
  • 2那彦群,汪迪,金杰,郭应禄,薛兆英,顾方六.选择性α_(1a)受体阻断剂治疗前列腺增生症[J].中华泌尿外科杂志,1996,17(6):327-329. 被引量:22
  • 3Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders [ J ]. J Urol, 2003, 170(2 Pt 1 ) :649-653.
  • 4Yamamoto T, Ghosh R, De Groat WC, et al. Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via alphal-adrenoceptors [ J ]. Eur J Pharmacol, 2001,414 ( 1 ) :31-35.
  • 5Yashiyama M, De Groat WC. Role of spinal alphal -adrenoceptor subtypes in the bladder reflex in anesthetized rats [ J]. Am J Physiol Regul Integr Comp Physiol, 2001, 280 (5): R1414-1419.
  • 6Hayashi T, Sakai Y, Saito K, et al. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia[ J]. Hinyokika Kiyo, 2002,48(1):7-11.
  • 7Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study[J]. J Urol, 2000, 163(4) :1134-1137.
  • 8Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin [ J ]. Urology, 2001,58 (4) :508-516.
  • 9Roehrboru CG. Alfuzosin:overview of pharmacokinetics,safety and efficacy of a clinically uroselective alpha-blocker [ J ]. Urology,2001,58(6 Suppl 1 ):55-63.
  • 10Mottet N, Bressolle F, Delmas V, et al. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration [ J ]. Eur Urol, 2003, 44(1) :101-105.

共引文献1460

同被引文献171

引证文献18

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部